| P2093 | author name string | Hiroyuki Sato | |
| | Jun Takada | |
| | Susumu Imai | |
| | Mitsuru Okuno | |
| | Kimihiro Yamaguchi | |
| | Daisuke Taguchi | |
| | Junko Shiroko | |
| | Shinobu Thanabashi | |
| P2860 | cites work | Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies | Q21144617 |
| | Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach | Q24673561 |
| | How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis | Q27008448 |
| | Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients | Q33214797 |
| | Inflammatory mediators in acute pancreatitis | Q33828947 |
| | 25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study | Q35203834 |
| | Prevention of post-ERCP pancreatitis: a comprehensive review | Q35790308 |
| | Systematic review and meta-analysis on the prophylactic role of non-steroidal anti-inflammatory drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis | Q35883015 |
| | A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis | Q35919742 |
| | Endoscopic sphincterotomy complications and their management: an attempt at consensus | Q37780048 |
| | Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis | Q37795680 |
| | Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis | Q38117589 |
| | Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. | Q38479517 |
| | Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis? | Q40386858 |
| | Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls | Q41603966 |
| | Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis | Q41778065 |
| | Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen | Q46378347 |
| | Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. | Q51741614 |
| | Risk factors for post-ERCP pancreatitis: a prospective, multicenter study | Q74568909 |
| | Risk Factors for Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography: A Meta-Analysis | Q79151845 |
| | Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial | Q83477164 |
| | Biliary stent placement is associated with post-ERCP pancreatitis | Q84571641 |
| | Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? | Q84580134 |
| P433 | issue | 16 | |
| P921 | main subject | Diclofenac | Q244408 |
| P304 | page(s) | 2289-2294 | |
| P577 | publication date | 2018-03-30 | |
| P1433 | published in | Internal Medicine | Q6047666 |
| P1476 | title | The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis. | |
| P478 | volume | 57 | |